Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables declines year over year
Q1 FY2026 accounts payables of $1.88M (cash outflow) fell 1.6% year over year, ahead of the -608.8% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at +124.3% a year.
Context
- Accounts payables amounted to 32.3% of revenue in FY2025, down 14.9 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -1.6% holds above the trailing-twelve-month pace of -608.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (3.92M) USD
- Year-over-year change
- -218.5%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.92M) | -218.5% |
| FY2024 | 2024-12-31 | 3.31M | +245.6% |
| FY2023 | 2023-12-31 | (2.27M) | -554.2% |
| FY2022 | 2022-12-31 | (347K) | -108.9% |
| FY2021 | 2021-12-31 | 3.9M | — |
Accounts Payables vs competitors
How PRLD compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -608.8% is the lowest of 10, against a peer median of +38.3%.
- Accounts payables amounts to 23.2% of revenue for PRLD, versus a peer median of 12.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.89M USD | -608.8% | +124.3% | 23.2% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $3.31M USD | +280.1% | +21.9% | — |
| LTM Mar 2026 | $3.06M USD | -161.7% | — | 9.3% | |
| LTM Mar 2026 | $2.51M USD | +12.5% | — | 1116.0% | |
| FY2025 | €2.46M EUR | — | -11.4% | 54.8% | |
| LTM Mar 2026 | $2.14M USD | +288.2% | — | 15.5% | |
| LTM Mar 2026 | $793K USD | -49.2% | -33.2% | 2.8% | |
| LTM Mar 2026 | $399K USD | +1230.0% | -34.4% | 0.6% | |
| LTM Mar 2026 | $370K USD | -77.8% | — | 3.3% | |
| LTM Mar 2026 | $325K USD | +38.3% | -33.1% | 550.8% | |
| LTM Mar 2026 | $197.49K USD | +121.5% | — | — | |
| Peer median (excluding PRLD) | — | +38.3% | -33.1% | 12.4% | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Depreciation & Amortization | 915K | 1.32M | 1.17M | 1.77M | 1.34M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.93M | 25.14M | 25.62M | 21.35M | 11.91M |
| Change in Working Capital | 3.63M | 932K | (10.48M) | 4.22M | 28.41M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.9M | (347K) | (2.27M) | 3.31M | (3.92M) |
| Other Working Capital | (278K) | 1.28M | (8.21M) | 911K | 32.33M |
| Other Non-Cash Items | 2.69M | 4.31M | (1.54M) | (3.05M) | 1.53M |
| Operating Cash Flow | (83.53M) | (83.73M) | (107.06M) | (102.89M) | (56.3M) |
| Capital Expenditures | (2.32M) | (3.02M) | (3.51M) | (764K) | (67K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (261.48M) | (119.22M) | (221.63M) | (52.69M) | (100.87M) |
| Sales of Investments | 0 | 203.93M | 190.5M | 143.65M | 154.39M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (263.8M) | 81.69M | (34.65M) | 90.19M | 53.46M |
| Debt Repayment | 0 | 0 | 0 | (395K) | (208K) |
| Common Stock Issued | 161.42M | 815K | 135.73M | 329K | 25.04M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.47M | 0 | 664K | (54K) | (17K) |
| Financing Cash Flow | 164.9M | 815K | 136.4M | (120K) | 24.82M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (182.44M) | (1.22M) | (5.31M) | (12.82M) | 21.97M |
| Free Cash Flow | (85.85M) | (86.75M) | (110.58M) | (103.65M) | (56.37M) |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.